Pyxis Oncology (NASDAQ:PYXS) Releases Earnings Results, Beats Estimates By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS) released its quarterly earnings results on Monday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06, FiscalAI reports. The business had revenue of $11.04 million during the quarter.

Pyxis Oncology Stock Performance

Pyxis Oncology stock traded up $0.09 during trading hours on Wednesday, reaching $1.45. 94,095 shares of the stock were exchanged, compared to its average volume of 718,865. The stock has a market cap of $90.28 million, a P/E ratio of -1.12 and a beta of 1.45. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.55. The firm’s 50 day moving average is $1.52 and its 200 day moving average is $2.51.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Maia Wealth LLC acquired a new position in shares of Pyxis Oncology during the fourth quarter worth about $25,000. Engineers Gate Manager LP purchased a new stake in Pyxis Oncology in the 4th quarter valued at approximately $26,000. Fox Run Management L.L.C. purchased a new stake in Pyxis Oncology in the 4th quarter valued at approximately $26,000. XTX Topco Ltd acquired a new position in Pyxis Oncology during the 2nd quarter worth approximately $40,000. Finally, LPL Financial LLC increased its position in Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after purchasing an additional 21,100 shares during the period. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Analyst Ratings Changes

PYXS has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Stifel Nicolaus lowered their price target on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Tuesday. Finally, Royal Bank Of Canada reduced their price objective on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.